

Pre-A

1 NeuroThree Therapeutics, Inc.
2
350 4V %

3

1

46) % 350 4V A

2

2025 3 5
4V A 4V %

3

~~M~~2 % / 25 2 8
 2 8 %07
 27
 / 25

LIRK0M

4V % / IR V* RH" / "
 791 - , SHNK 0QMH, 791 , SHNK 0QMH

LIRK0M			
) 73 4			

4V %

46) %

4V %

2 I VS8LVI 8LIVETI M -RG

2 I VS 8LIVETI M -RG

5 NeuroThree Therapeutics, Inc.

LIRKOM

6

1.01

1,250 Pre-A

350

1.02

15

ODI

5

2.01

2.02

(i)

(ii)

10

B

3.01

3.03

a (i)

100%

(ii)

100%

100%

(iii)

3.03(a)

b

c

3.04

(i)

(ii)

3.05

a

b

1933

4.01

4.03

5.01

5.02

5.04 ROFN

a

H. Lundbeck

A/S 2023 4 20

0 %*

[N3T040245]

63 *2

63 *2

b

ROFN

30

ROFN

90

63 *2

c

ROFN

ROFN

ROFN

60

ROFN

ROFN

6.01

6.03

6.04

(ii) (i)

6.05

6.06

6.07

6.08

7.01

7.02

7.03

7.04

7.05

(i)

(ii)

(iii)

(iv)

8.01

a

(i)

(ii)

8.02

(i)

(ii)

8.01

8.02

8.01

8.02

8.03

8.04

8.05

8.06

8.08

8.09

8.10

8.14

8.16

a

30

8.16(b)

b

(a)
, / -%

HKIAC

(b)

8.18

(i)

12

(ii) (iii)

(a)

12

(b)

15

1

2

1

2025 3 5

2

3

4

4V-A

5

2025 3 5